Quantcast

Latest Genentech Stories

2014-10-29 08:32:46

DUBLIN, Oct. 29, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global and China Monoclonal Antibody Industry Report, 2014-2019" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biotech drugs with the fastest CAGR in recent years. Global...

2014-10-22 23:06:39

RnRMarketResearch.com adds “Perjeta & Kadcyla (HER2-Positive Breast Cancer) – Forecast and Market Analysis to 2023” to its store. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market. Dallas, Texas (PRWEB) October 22, 2014 "Perjeta (HER2-Positive Breast Cancer) – Forecast and Market Analysis to 2023" HER2-positive breast cancer is the second most common cancer in...

2014-10-21 23:09:47

ChinaMarketResearchReports.com adds Latest Report on “Global and China Monoclonal Antibody Industry Report, 2014-2019” to its store. Inquire for discount on this report at http://www.chinamarketresearchreports.com/contacts/inquiry.php?name=114942 Dallas, TX (PRWEB) October 21, 2014 Despite world-wide economic downturn and great changes in exchange rate, benefiting from robust market demand, global monoclonal antibody market size exceeded USD 80 billion in 2013, still one of biotech...

2014-10-21 12:32:19

Genentech, Amgen, Igenica, and 8 Additional California Companies Scheduled to Present SAN DIEGO, Calif., Oct. 21, 2014 /PRNewswire-iReach/ -- Antibody-drug conjugates (ADCs) are one of the most exciting new classes of cancer therapeutics because they combine the potency of small molecules with the specificity of antibodies. California's culture of innovation, as well as access to world class drug discovery and development expertise, has accelerated progress in ADC therapeutics, a...

2014-10-20 16:26:25

Ophthotech/Novartis's Fovista Will Exceed $500 Million in 2023 Sales as a Treatment for the Wet Form of the Disease, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 20, 2014 /PRNewswire/ -- Decision Resources Group finds that the market for age-related macular degeneration (AMD) pharmacotherapies will expand 6 percent annually to reach nearly $9 billion in 2023 in the G7 pharmaceutical markets (United States, France, Germany, Italy, Spain, the United Kingdom and...

2014-10-17 08:25:24

TARRYTOWN, N.Y., Oct. 17, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that in the National Institutes of Health (NIH) sponsored, Diabetic Retinopathy Clinical Research Network (DRCR.net) comparative effectiveness study in patients with Diabetic Macular Edema (Protocol T), EYLEA(®) (aflibercept) Injection demonstrated a significantly greater improvement in mean change in best-corrected visual acuity (BCVA) from baseline at 52 weeks compared to both...

2014-10-08 08:26:24

-- Fourth indication for injection treatment that can stabilize and improve vision(1) -- mCNV a leading cause of visual impairment among those 20-50 years of age(9) Since its launch in Canada in 2007, Lucentis(®) has treated more than 100,000 eyes across all approved indications(3 ) DORVAL, QC, Oct. 8, 2014 /CNW/ - Novartis Pharmaceuticals Canada Inc. announced today that Lucentis(®) (ranibizumab), the treatment for several major causes of vision loss, has been...

2014-09-29 16:23:53

In the news release, The Gastric Cancer Market is Expected to More Than Triple Over the Next Ten Years, Capturing Nearly $3.8 million by 2023, issued 18-Sep-2014 by Decision Resources Group over PR Newswire, we are advised by the company that the headline should read $3.8 billion rather than $3.8 million as originally issued inadvertently. The complete, corrected release follows: The Gastric Cancer Market is Expected to More Than Triple Over the Next Ten Years, Capturing Nearly $3.8 billion...

2014-09-29 00:21:23

BASEL, Switzerland, Sept. 29, 2014 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and InterMune, Inc. (NASDAQ: ITMN) today announced that Roche's wholly owned subsidiary Klee Acquisition Corporation has accepted for payment all shares validly tendered pursuant to its tender offer for all outstanding shares of common stock of InterMune, Inc. at USD 74.00 per share in cash. The tender offer expired at 12:00 midnight, New York City time, at the end of the day on 26 September 2014,...

2014-09-18 12:29:19

Fovista and Abicipar Pegol Will Need to be Priced Competitively to Current Agents to Garner Favorable Tier Placement, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 18, 2014 /PRNewswire/ -- Decision Resources Group finds that Regeneron's Eylea, the most recently launched anti-vascular endothelial growth factor (VEGF) agent for wet AMD, is equally likely to be covered on commercial and Medicare Advantage plans as Genentech's Lucentis, which is the standard of care...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related